Open Nav

Zosano Pharma Corporation

  • John Walker, Zosano Pharma Corporation

Program and Company update

  • Date:Wednesday, October 17
  • Time:3:15 PM - 3:30 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Zosano Pharma (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies that deliver rapid systemic absorption using a novel and proprietary technology called Adhesive Dermally-Applied Microarray (“ADAM™”) with the potential to transform patient lives and advance patient care. M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology. Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan. The drug-coated microneedles physically break through the stratum corneum and penetrate into the epidermis and dermis, where the dry drug coating is dissolved by the surrounding skin interstitial fluid. In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints.
  • Company
  • Company HQ City:Fremon
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Market Cap:$52,000,000
  • Ticker:ZSAN
  • Exchange:Nasdaq
  • CEO/Top Company Official:John Walker
  • Year Founded:2006
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :M207 (zolmitriptan coated microarrays)
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :Multiple
  • Additional Information/Comments:Presentation will be conducted by our CEO, John Walker.
John Walker
Zosano Pharma Corporation